Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1345 RSV Vaccine in Pregnant Women and Infants
NCT06143046Phase 2Completed
- Sponsor
- Moderna Inc
- Start
- Nov 2023
- Primary completion
- May 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 8
01
Overview
A Phase 2 trial of RNA-100-AR02 in respiratory syncytial virus infection (RSV), sponsored by Moderna Inc. Started Nov 2023; status: completed.
02
Drugs
RNA-100-AR02
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06143046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06143046.